Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

Document › Details

MorphoSys AG. (10/13/20). "Press Release: MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds [Not for US, AU, ZA, JP, et al.]". Planegg.

	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Organisation 2	Goldman Sachs International
	Group	Goldman Sachs (Group)
	Product	BIOTECH
	Product 2	investment banking
	Person	Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme)

Original document
accessed by [iito] on 2020-10-14

Record changed: 2020-10-16

More documents for MorphoSys (Group)

[1] MorphoSys AG. (10/13/20). "Press Release: Ad hoc – MorphoSys AG Launches an Offering of approx. EUR 325 Million Convertible Bonds". Planegg....
[2] MorphoSys AG. (9/30/20). "Press Release: MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020". Planegg....
[3] MorphoSys AG. (8/1/20). "Press Release: FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Planegg & Wilmington, DE....
[4] MorphoSys AG. (7/14/20). "Press Release: MorphoSys' Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis". Planegg....
[5] SHS Gesellschaft für Beteiligungsmanagement mbH. (4/21/20). "Press Release: SHS Appoints Sascha Alilovic as Managing Partner"....
[6] MorphoSys AG. (4/21/20). "Press Release: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer". Planegg....
[7] MorphoSys AG. (4/6/20). "Press Release: MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures". Planegg....
[8] MorphoSys AG. (3/2/20). "Press Release: FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL". Planegg....
[9] MorphoSys AG. (2/4/20). "Press Release: MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.". Planegg....
[10] MorphoSys AG. (1/13/20). "Press Release: MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab". Planegg & Wilmington, DE....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top